Solian Tab. 400mg

Ingredient

Amisulpride

Content

400mg

Indication

Treatment of schizophrenia

Stilnox CR Tab. 12.5mg

Ingredient

Zolpidem Tartrate

Content

12.5mg

Indication

Short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Stilnox CR Tab. 6.25mg

Ingredient

Zolpidem Tartrate

Content

6.25mg

Indication

Short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Stilnox Tab. 10mg

Ingredient

Zolpidem Tartrate

Content

10mg

Indication

Short-term treatment of insomnia in adults

Strensiq

Ingredient

Asfotase-alfa

Content

18 mg/0.45 mL, 28 mg/0.7 mL, 40 mg/mL, or 80 mg/0.8 mL solution in single-dose vials

Indication

Long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia to treat the bone manifestations of the disease. Pediatric includes perinatal/infantile (0-6 months of age at the time of onset) and juvenile (6 months to 18 years of age at the time of onset).

Suglat^®Tablet 50mg

Ingredient

Ipragliflozin L-proline (In-house spec.) 64.3mg (50 mg as Ipragliflozin)

Content

Light purple, round, film-coated tablet

Indication

This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes.
– Monotherapy
– Combination therapy

Telmidiqual^®

Ingredient

Telmisartan/ Amlodipine

Content

40/5mg 40/10mg 80/5mg

Indication

Treatment of essential hypertension.

Telmidiqual is indicated in adult patients whose blood pressure is not adequately controlled on Telmisartan or Amlodipine monotherapy

Tenelia M SR Tab. 10/500mg

Ingredient

Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

Content

Teneligliptin Hydrobromide Hydrate 15.5mg (10mg as Teneligliptin), Metformin Hydrochloride 500mg

Indication

This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of teneligliptin and metformin.

Tenelia M SR Tab. 10/750mg

Ingredient

Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

Content

Teneligliptin Hydrobromide Hydrate 15.5mg (10mg as Teneligliptin), Metformin Hydrochloride 750mg

Indication

This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of teneligliptin and metformin.

Tenelia M SR Tab. 20/1000mg

Ingredient

Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

Content

Teneligliptin Hydrobromide Hydrate 31mg (20mg as Teneligliptin), Metformin Hydrochloride 1000mg

Indication

This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of teneligliptin and metformin.